Scope<\/strong><\/p>\n The\u00a0European Journal of Neurodegenerative Diseases (EJND)\u00a0<\/em>is an international peer-reviewed Open Access clinical and research journal published online every four months.<\/p>\n EJND<\/em> covers a broad range of topics and publishes Original Articles, Reviews, Mini-Reviews, Brief Reports, Case Reports, and Letters focusing on morphological, ultrastructural, physiological, pathophysiological, molecular, biochemical, bioenergetics, pharmacological, therapeutic, and regulatory aspects of neurodegenerative diseases and craniofacial research and clinical application.<\/p>\n <\/p>\n Third-party submissions<\/strong><\/p>\n Where an individual who is not listed as an author submits a manuscript on behalf of the author(s), a statement must be included in the Acknowledgements section of the manuscript and in the accompanying cover letter. The statements must:<\/p>\n Where appropriate, Biolife Publisher reserves the right to deny consideration to manuscripts submitted by a third party rather than by the authors themselves.<\/p>\n <\/p>\n Research ethics and patient consent<\/strong><\/p>\n Please see the dedicated page on EJND<\/em>‘s Ethics Policy and Informed Consent<\/a><\/strong><\/p>\n Medical research involving human subjects must be conducted according to the\u00a0World Medical Association Declaration of Helsinki<\/a>.<\/p>\n Submitted manuscripts should conform to the\u00a0ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals<\/a>, and all papers reporting animal and\/or human studies must state in the methods section that the relevant Ethics Committee or Institutional Review Board provided (or waived) approval. Please ensure that you have provided the full name and institution of the review committee, in addition to the approval number.<\/p>\n For research articles, authors are also required to state in the methods section whether participants provided informed consent and whether the consent was written or verbal.<\/p>\n Information on informed consent to report individual cases or case series should be included in the manuscript text. A statement is required regarding whether written informed consent for patient information and images to be published was provided by the patient(s) or a legally authorized representative.<\/p>\n Please also refer to the\u00a0ICMJE Recommendations for the Protection of Research Participants<\/a>.<\/p>\n All research involving animals submitted for publication must be approved by an ethics committee with oversight of the facility in which the studies were conducted. The journal has adopted the\u00a0Consensus Author Guidelines on Animal Ethics and Welfare for Veterinary Journals<\/a>\u00a0published by the International Association of Veterinary Editors.<\/p>\n <\/p>\n Declarations<\/strong><\/p>\n **Please note that all manuscripts should be accompanied by a separate document entitled ‘Author Declaration Form’.**\u00a0<\/strong><\/p>\n This should be submitted with your manuscript file and saved as ”Author Declaration Form EJND<\/em>‘ , and please note that manuscripts that do not include this form will be returned.<\/p>\n Please download the Submission form HERE<\/u><\/a> and complete.\u00a0<\/strong><\/p>\n <\/p>\n Clinical trials<\/strong><\/p>\n European Journal of Neurodegenerative Diseases<\/em> conforms to the ICMJE requirement<\/a> that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment as a condition of consideration for publication. The trial registry name and URL and registration number must be included at the end of the abstract.<\/p>\n <\/p>\n Reporting guidelines<\/strong><\/p>\n The relevant reporting guidelines should be followed depending on the type of study. Resources can be found in NLM’s Research Reporting Guidelines and Initiatives<\/a>.<\/p>\n <\/p>\n Corrections, retractions, and editorial expressions of concern<\/strong><\/p>\n We recognize our responsibility to correct errors that we have previously published. Our policy is to consider refutations (readers’ criticisms) of primary research papers, and to publish them (in concise form) if and only if the author provides compelling evidence that a major claim of the original paper was incorrect. Refutations are peer-reviewed, and where possible they are sent to the same referees who reviewed the original paper. A copy is usually also sent to the corresponding author of the original paper for signed comments. Refutations are typically published in the Communications Arising section of Biolife Publisher, sometimes with a brief response from the original authors. Some submitted refutations are eventually published as retractions by the paper’s authors.<\/p>\n Complaints, disagreements over interpretation and other matters arising should be addressed to the Editor of EJND <\/em>by contacting ejnd@biolife-publisher.it<\/strong><\/a>. Because debates over interpretation are often inconclusive, we do not automatically consider criticisms of review articles or other secondary material, and in the event that we decide to publish such a criticism we do not necessarily consult the original authors. Editorial decisions in such cases are based on considerations of reader interest, novelty of arguments, integrity of the publication record and fairness to the parties involved. Publication may take various forms at the discretion of the editor.\u00a0 Biolife Publisher considers correspondence relating to all review-type articles.<\/p>\n Corrections are published for significant errors in non-peer-reviewed content of Biolife Publisher journals at the discretion of the editors. Readers who have identified such an error should send an email to the general email address of the journal, clearly stating the publication reference, title, author and section of the article, briefly explaining the error.<\/p>\n\n